Drug Approval | June 15, 2022
Eli Lilly gets FDA approval for alopecia drug
Alopecia areata usually presents as a few small bald patches in the head
Alopecia areata usually presents as a few small bald patches in the head
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Subscribe To Our Newsletter & Stay Updated
